Screening the High-risk Population of Breast Cancer Brain Metastasis Accompanied with Severe Peritum

来源 :2016年北京市肿瘤放疗年会 | 被引量 : 0次 | 上传用户:liweibo2555
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective:To determine the high-risk population of breast cancer brain metastasis accompanied with severe peritumoral brain edema, and to probe into the effects of peritumoral brain edema degree on the prognosis for breast cancer patients with brain metastasis.Methods:The clinical features of the breast cancer patients with brain metastasis accompanied with peritumoral brain edema in our department were retrospectively analyzed, and the edema index (EI) was adopted to represent the peritumoral edema degree, the calculation formula of which was EI=(Vedema+Vtumor) / Vtumor.EI was treated as the dependent variable, and rank sum test was conducted on factors such as age, diameter of the metastasis,reinforcing features of the metastasis, position of the metastasis in the brain, whether the lesion was regular,duration from diagnosis of breast cancer to brain metastasis, ER, PR and Her-2, so as to analyze the influence factors of EI.Kaplan-Meier method was adopted to analyze the effects of EI on the prognosis for breast cancer patients with brain metastasis, and the Coxs proportional hazard model was applied in multivariate analysis.Results:Altogether 58 cases of breast cancer patients with single brain metastasis were enrolled in this research in accordance with the inclusion and exclusion criteria, with the median age of 44 years old (range: 26 to 61 years old), and the median EI of 3.01.Patients with negative ER, those with the age of≥45 years old, and those with irregular lesions were the independent factors that influenced EI (Mann-Whitney rank sum test, p<0.05).The univariate and multivariate analysis indicated that EI was not related to the prognosis for breast cancer patients with brain metastasis.Conclusion:Breast cancer patients with brain metastasis who have negative ER, the age of≥45 years old, and irregular brain metastases are the high risk population of severe peritumoral brain edema;and the EI is not related to the prognosis for breast cancer patients with brain metastasis.
其他文献
Background.The aim of the study was to evaluate short-term safety and efficacy of simultaneous modulated accelerated radiation therapy (SMART) delivered via helical tomotherapy in patients with nasoph
目的:鼻咽癌是我国头颈部常见的恶性肿瘤,放射治疗是其首选治疗方法.鼻咽癌放射治疗后常损伤听力、咽鼓管及前庭功能,并伴有不同程度的口干、皮肤破损,严重影响战斗机飞行安全,致使飞行员医学停飞.查阅相关的文献资料,未见采用螺旋断层放疗技术(HT,HelicalTomotherapy)治疗飞行员鼻咽癌后复飞的报道.材料与方法:针对2014年11月在院确诊鼻咽癌的战斗机飞行员,采用HT行根治性放射治疗,定期
目的:回顾性分析单中心头颈部黏膜恶性黑色素瘤的临床特征及治疗疗效.材料和方法:回顾性分析1981-2015年间医院收治的161例初诊无远地转移的头颈部黏膜恶性黑色素瘤的临床资料.其中男94例,女67例,发病年龄19-83岁(中位数54岁).最常见的原发部位为鼻腔(55%)和口腔(30%),其余部位包括副鼻窦(6%),眼睑(5%),鼻咽(2%)和口咽(2%).按第七版AJCC头颈部黏膜恶性黑色素瘤分
Purpose:The present clinical trial was designed to evaluate the efficacy and safety of concurrent helical tomotherapy (HT) with cetuximab followed by adjuvant chemotherapy with docetaxel and cisplatin
目的:早期乳腺癌保乳术后患者的预后与放疗获益,分析相关因素对预后的影响.方法:回顾分析医院1999年至2013年收治的1697例保乳术后早期乳腺癌患者,均未行新辅助化疗.中位年龄46岁(22-88).20例(1.1%)手术切缘阳性.术后病理分期pT1和pT2分别为1271例(74.9%)和426例(25.1%),pN0,pN1、pN2和pN3分别为1234例(72.7%)、334例(19.7%)、
目的:每日两次放疗(45Gy/30f,1.5Gy/f)或每日一次放疗(60-70Gy/30-35f,2.0Gy/f)联合EP方案化疗是NCCN指南局限期小细胞肺癌(LS-SCLC)的标准治疗方案.CONVERT研究比较了LS-SCLC每日两次放疗(45Gy/30f)与每日一次放疗(66Gy/33f)联合EP方案化疗的疗效,结果显示:每日两次放疗与每日一次放疗3年生存率无显著性差异(43%和39%)
目的:通过对射波刀呼吸追踪治疗肺部肿瘤的应用、体会,总结射波刀对肺部肿瘤治疗的优势,为进一步的应用、推广提供临床依据.方法:选择2013年12月至2015年10月收治的42例进行射波刀呼吸追踪治疗的肺部肿瘤患者,观察评估本组患者3个月和6个月的有效率和毒副反应发生情况.结果:42例患者均顺利完成治疗.3个月有效率为94%,6个月有效率为95%.发生急性放射性肺炎2例约占本组病例的5%、急性放射性食
目的:比较肺癌放疗过程中四维CT与传统方法勾画靶区的治疗计划差异性.方法:选取医院2013-01/2013-12间20例肺癌放疗患者为研究对象,对其进行四维CT与普通螺旋CT扫描,并且应用两种方法划定靶区与制定治疗计划,比较两种不同方法测定靶区的体积,分析其差异.结果:四维CT扫描勾画计划靶区体积为(277.4±33.6)cm3,普通螺旋CT扫描勾画计划靶区体积为(295.3±34.1)cm3.计
目的:探讨程序性死亡受体(PD)-1单克隆抗体治疗食管癌术后、化疗后转移性淋巴结的疗效.方法:回顾性分析1例使用PD-1单克隆抗体(pembrolizumab)治疗食管癌术后、化疗后淋巴结转移的临床资料.结果:患者食管癌术后、化疗后仍存在淋巴结转移,化疗后4个月内给予pembrolizumab治疗(100mg静脉滴,每2周一次),治疗后4周期后疗效评价为SD,8周期后疗效评价为PR.结论:食管癌术
目的:对SCLC患者外周血微环境中肿瘤相关细胞因子IL-2,IL-6,TGF-β1,HIF-1,PD-1,PD-L1,CTLA-4在治疗前,以及治疗的第1-7周期的动态表达进行检测,从细胞因子水平明确肿瘤患者全身免疫状况;为免疫治疗与化疗的结合寻找最佳切入点,并对治疗决策的制定提供依据.方法:收集43例ED/LD期SCLC患者外周血,利用ELISA方法检测该组患者外周血中IL-2,IL-6,TGF